文献速递系统性红斑狼疮

阿尼鲁单抗药代动力学与系统性红斑狼疮疗效及安全性的关系

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

基于TULIP-1和TULIP-2两项3期随机对照试验的汇总数据,分析中重度SLE患者静脉注射阿尼鲁单抗后血药浓度与52周疗效及安全性的关系。结果显示较高平均血清浓度预测更好的BICLA应答,且300 mg剂量在各浓度亚组均优于安慰剂,未发现暴露驱动的安全性事件。

要点

  • 较高阿尼鲁单抗平均血清浓度与更好的BICLA应答相关。
  • 300 mg阿尼鲁单抗在各浓度亚组中BICLA和SRI(4)应答均优于安慰剂。
  • 至52周未发现暴露驱动的关键安全性事件。

核心结论

  • 较高平均血清浓度预测更好的疗效,但300 mg阿尼鲁单抗在各浓度亚组中均显示一致优于安慰剂的BICLA和SRI(4)应答。
  • 未发现暴露驱动的安全性事件。

研究设计与样本

  • 汇总TULIP-1和TULIP-2两项随机、安慰剂对照、52周3期试验数据,静脉注射阿尼鲁单抗每4周一次共48周。
  • 接受阿尼鲁单抗150 mg者91例、300 mg者356例,安慰剂者366例;574例完成治疗,其中470例IFNGS高。
  • 采用平均边际效应逻辑回归比较各平均血清浓度四分位/三分位组的BICLA或SRI(4)应答率,并图形评估暴露与关键安全性事件的关系。

主要发现

  • 在暴露-疗效分析中,各平均血清浓度亚组及所有分析人群均观察到阿尼鲁单抗300 mg较安慰剂在BICLA和SRI(4)应答上的治疗差异。
  • 逻辑回归识别平均血清浓度为预测BICLA应答的显著协变量,较高浓度预测更大疗效。
  • 至52周,接受阿尼鲁单抗150或300 mg的患者中无暴露驱动关键安全性事件发生率的证据。

关键数值与推荐

  • 阿尼鲁单抗300 mg在各平均血清浓度亚组中BICLA和SRI(4)应答均优于安慰剂。
  • 较高平均血清浓度预测更好的BICLA应答。
  • 未发现暴露驱动安全性事件。

临床怎么用

  • 支持阿尼鲁单抗300 mg静脉注射每4周一次在中重度SLE患者中的疗效一致性,无需根据血药浓度调整剂量。
  • 临床应用中无需常规监测阿尼鲁单抗血药浓度以预测疗效或安全性。

局限性

  • 原文未报告暴露-反应分析的具体数值、置信区间或P值。
  • 安全性分析为图形评估,未提供统计检验。
  • 仅为两项试验的汇总分析,未报告外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from two phase 3 trials. METHODS: TULIP-1 and TULIP-2 were randomized, placebo-controlled, 52-week trials of intravenous anifrolumab (every 4 weeks for 48 weeks). For the exposure-response analysis, BILAG-based Composite Lupus Assessment (BICLA) or SLE Responder Index [SRI(4)] response rates at week 52 in each quartile/tertile of average anifrolumab serum concentration (Cave) were compared for anifrolumab and placebo in all-comers, patients who completed treatment, and IFN gene signature (IFNGS)-high patients who completed treatment, using average marginal effect logistic regression. Relationships between exposure and key safety events were assessed graphically. RESULTS: Of patients in TULIP-1/TULIP-2 who received anifrolumab (150 mg, n = 91; 300 mg, n = 356) or placebo (n = 366), 574 completed treatment, of whom 470 were IFNGS high. In the exposure-efficacy analyses, BICLA and SRI(4) treatment differences favouring anifrolumab 300 mg vs placebo were observed across Cave subgroups and all analysis populations. Logistic regression identified Cave as a significant covariate for predicted BICLA response, as higher anifrolumab Cave predicted greater efficacy. There was no evidence of exposure-driven incidence of key safety events through week 52 in patients receiving anifrolumab 150 or 300 mg. CONCLUSION: While higher Cave predicted greater efficacy, consistent positive benefit favouring anifrolumab 300 mg vs placebo was observed in BICLA and SRI(4) responses across Cave subgroups in the TULIP trials. There was no evidence of exposure-driven safety events. CLINICALTRIAL.GOV NUMBERS: NCT02446912, NCT02446899.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chia YL, Zhang J, Tummala R, et al. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022. PMID: 34528084. doi:10.1093/rheumatology/keab704

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。